Eli Lilly & Co. has partnered with the Swiss neurodegenerative disease specialist AC Immune SA to develop tau-aggregation inhibitors, which are small molecules that could offer big potential as combination therapies with amyloid-beta antibodies. Combination therapy is where the industry increasingly is interested in going in Alzheimer's disease as clinical trial failures for various monotherapies pile up.
"It's the first small molecule in the world which directly interacts with pathological tau," AC Immune CEO Andrea Pfeifer said...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
